#South Korea #Seoul #Botulax #Hugel Inc #THE CHAEUM

Hugel Inc. Reports Unprecedented Annual Results for 2025

Hugel Inc., a prominent player in the global medical aesthetics industry and publicly traded in South Korea, has announced remarkable preliminary consolidated financial results for the fiscal year 2025. The company achieved net sales of KRW425.1 billion, marking a significant increase of 14% compared to the previous year. Additionally, Hugel's operating profit reached KRW201.6 billion, reflecting a 21.3% year-on-year growth.

The success is primarily attributed to the surging global demand for Hugel's flagship products, particularly the botulinum toxin known as Botulax and its line of hyaluronic acid dermal fillers, including THE CHAEUM and BYRYZN. The company also noted significant growth in its cosmetic offerings, showcasing products like WELLAGE and BYRYZN BR—each contributing to the robust financial performance brought forth by a rapidly expanding consumer base.

To delve deeper into the numbers, 2025's total sales from the botulinum toxin category amounted to KRW233.8 billion, while the dermal fillers generated KRW129.7 billion and cosmetics added KRW61.6 billion to the overall figures. The synergistic performance of the core products resulted in combined sales totaling to KRW363.5 billion, up 10% year-on-year. Hugel's overseas operations played a crucial role, as net sales from international markets reached KRW268.5 billion, a remarkable 22% increase from 2024, with exports of toxin and dermal fillers rising to 74% in 2025, up from 66% the previous year.

In terms of regional performance, the Americas, particularly the United States and Brazil, demonstrated impressive growth. The combined sales of the toxin and dermal fillers in this region hit KRW67.9 billion, skyrocketing by 105% year-on-year, while the fourth quarter alone saw a staggering spike close to 310% year-on-year, culminating in an impressive KRW29.2 billion for that quarter.

Hugel's strategic aspirations aim at fostering further global expansion with an enhanced focus on growing both revenue and profitability. Carrie Strom, Hugel’s President and Global CEO, emphasized the importance of the United States—being the world's largest market for botulinum toxin—as a priority for their growth strategy. To capitalize on this potential, Hugel plans to implement a hybrid sales model that combines traditional partner distribution with direct sales to secure a competitive edge and increase market penetration.

Reflecting on the success, Strom stated, "Building on our strong global competitiveness, Hugel achieved record-breaking results surpassing KRW400 billion in annual net sales for the first time. We are committed to strengthening our global growth foundation by focusing on the Big 4 markets this year—the US, China, Europe, and Brazil."

In summary, 2025 results not only mark a financial milestone for Hugel but also signify the company’s relentless pursuit of operational excellence and global market leadership. For their fourth quarter performance, Hugel demonstrated continued growth with net sales rising to KRW119.1 billion and operating profit increasing to KRW58.6 billion, up 21.3% and 26.2% year-on-year, respectively.

About Hugel

Founded in 2001, Hugel holds a significant status in the medical aesthetics sphere, with a specialization in injectables for skin enhancement, including botulinum toxin, hyaluronic acid fillers, and skin boosters, alongside absorbable sutures and cosmetic products. The company maintains a strong commitment to quality and safety, with operations spanning approximately 70 countries and nine subsidiaries located across countries such as the US, Australia, Canada, and various Asian markets. With a robust market trajectory and proactive growth strategies, Hugel is well-positioned for sustained advancement and global influence.